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ABSTRACT Pulmonary embolism (PE) is common and guidelines recommend outpatient care only for
PE patients with low predicted mortality. Outcomes for patients with intermediate-to-high predicted
mortality managed as outpatients are unknown.
Electronic records were analysed for adults with PE managed on our ambulatory care unit over 2 years.
Patients were stratified into low or intermediate-to-high mortality risk groups using the Pulmonary
Embolism Severity Index (PESI). Primary outcomes were the proportion of patients ambulated, 30-day all-
cause mortality, 30-day PE-specific mortality and 30-day re-admission rate.
Of 199 PE patients, 74% were ambulated and at 30 days, all-cause mortality was 2% (four out of 199)
and PE-specific mortality was 1% (two out of 199). Ambulated patients had lower PESI scores, better vital
signs and lower troponin levels (morning attendance favoured ambulation). Over a third of ambulated
patients had an intermediate-to-high risk PESI score but their all-cause mortality rate was low at 1.9%
(one out of 52). In patients with intermediate-to-high risk, oxygen saturation was higher and pulse rate
lower in those who were ambulated. Re-admission rate did not differ between ambulated and admitted
patients.
Two-thirds of patients with intermediate-to-high risk PE were ambulated and their mortality rate
remained low. It is possible for selected patients with intermediate-to-high risk PESI scores to be safely
ambulated.
@ERSpublications
In a cohort of 199 patients with pulmonary embolism (PE), 52 were managed as outpatients
despite an intermediate-to-high risk of mortality. Only 1 outpatient died within 30 days and not
from PE, suggesting opportunities for increased ambulatory care. http://ow.ly/4p4D30oaNkr
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PULMONARY VASCULAR DISEASES
Introduction
Pulmonary embolism (PE) is potentially fatal and accounted for over 27000 hospital admissions in the UK
in 2011 and consumption of around 250000 bed days [1]. The success of anticoagulant treatments that
can be safely administered intermittently out of hospital has made outpatient management of PE a
technical possibility [2]. Managing PE on an outpatient basis could reduce bed-occupancy, reduce
healthcare costs and improve patient satisfaction, without affecting safety or efficacy [3].
Acute PE is heterogenous in its severity and scoring systems have been developed and validated to stratify
risk of mortality, recurrence and major bleeding [4–6]. The Pulmonary Embolism Severity Index (PESI)
score is calculated from 11 clinical parameters to determine the risk of mortality at 30 days and has been
extensively validated [4, 7–9]. The PESI scoring system classifies patients into five levels, with levels one
and two grouped as “low risk” (score <86, 30-day mortality 0–1%) and levels three, four and five grouped
as “intermediate-to-high risk” (score ⩾86, 30-day mortality 3.1–23.9%) [4, 10]. A randomised controlled
trial demonstrated non-inferiority of outpatient management for patients with a low risk PESI score [7].
The European Society of Cardiology (ESC) and the British Thoracic Society (BTS) used this evidence in
their recent guidelines on PE management to recommend that patients with a low risk PESI score be
considered for outpatient management and patients with intermediate-to-high risk be admitted [11, 12].
For example, the ESC guidelines recommend that patients with intermediate-to-high risk PESI scores be
admitted for close monitoring in case rescue reperfusion therapy is required; however, no mortality benefit
from this approach has been demonstrated [11, 13]. Nevertheless, there is an assumption that a predicted
mortality threshold exists, whereby inpatient care may be safer and there is a lack of evidence as to whether
some patients with intermediate or high risk PESI scores may be safely managed on an outpatient basis.
The introduction of ambulatory care units in the UK has provided an opportunity for the management of
PE on an outpatient basis, allowing for diagnosis, monitoring and initiation of treatment over a period of
several hours. At our ambulatory medical unit within a major teaching hospital we operated an inclusive
acceptance policy for referrals with suspected PE, whereby a senior ambulatory clinician triaged referrals
without rigid exclusion criteria. Our institutional guidelines allowed for patients with non-massive PE and
intermediate-to-high risk PESI scores to be managed on an ambulatory basis if this was determined to be
appropriate after shared decision-making between the medical consultant and the patient. In this study we
report the clinical characteristics and outcomes for all patients diagnosed with an acute PE who were
managed on the ambulatory medical unit. We present the outcomes in this cohort, stratified by PESI score.
Methods
We operated an inclusive referral system to the ambulatory assessment unit (AAU), accepting all adult
patients for whom ambulation was considered likely. Referrals were triaged by the AAU consultant
physician or the medical registrar during the day and by the senior house officer overnight. Direct referrals
were accepted from the emergency department, general practitioners, paramedics, specialist nurses,
community hospital based ambulatory units and outpatient clinics. Additionally, non-ambulatory patients
residing in community hospitals could also be referred for urgent cross-sectional imaging on a day-case
basis when there was no local imaging availability. Patients with suspected acute PE or incidental findings
of PE were investigated and managed according to the hospital’s venous thromboembolism protocol.
We ascertained all patient episodes on the AAU with a primary diagnosis code of “pulmonary embolism
without cor pulmonale” between January 01, 2016 and December 21, 2017 (there were no episodes where
the presence of PE-related cor pulmonale was coded). For patients who had more than one episode with a
primary diagnosis of PE we included only the first episode, giving a total of 275 patients. We excluded
patients who were either miscoded with the primary diagnosis of PE or who were transiently
accommodated on the AAU during their discharge from an inpatient unit bed, resulting in the exclusion
of 76 subjects. To evaluate the trajectory and safety of care for patients with PE, we assessed the primary
outcomes: ambulation status at discharge, all-cause mortality at 30 days, PE-specific mortality at 30 days
and re-admission rate at 30 days (including ambulatory unit attendances but excluding emergency
department attendances not leading to admission).
We also ascertained baseline demographic parameters, co-morbidities, markers of PE severity using the
PESI scoring system and the extent of PE on imaging and with biomarkers (troponin and brain natriuretic
protein (BNP)) [4]. For clinical observations, the first recorded value on the AAU was used. The decision
to ambulate patients who had been accepted onto the AAU and diagnosed with PE was made by the AAU
consultant physician. We collected data from the hospital electronic patient record, collated the data in
Microsoft Excel (Microsoft Corp, Redmond, WA, USA) and analysed the data using the Pandas module
(https://pandas.pydata.org). Statistical analysis was performed using Fisher’s exact test for categorical data,
where one or more cells of the contingency table contained less than five outcomes, and the Chi-squared
test with Yates correction for all other cases. For continuous variables an unpaired two-tailed t-test was
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performed. The p-value threshold for significance was set at 0.05. The study was approved by the hospital
clinical governance department and was not deemed to need additional research ethics approval because it
was a retrospective service evaluation.
Results
Clinical characteristics and mortality in AAU patients diagnosed with PE
We identified 199 patients with a primary diagnosis of PE who were managed on the AAU. Of these, 95
(47.7%) were male and the mean age was 62.3 years with a range from 19–93 years. The D-dimer was
abnormal in all 147 tested patients. Computed tomography pulmonary angiography (CTPA) was performed
in 189 patients (95.0%) and nuclear perfusion scintigraphy was performed in a further nine patients (4.5%).
One patient had a fatal cardiac arrest before imaging could be completed. PE was an incidental finding on
computed tomography (CT) scanning performed for other indications in 13 patients (6.5%). The number of
ambulated patients was 148 (74%) and 30-day all-cause mortality was 2% (four out of 199 patients), while
30-day PE-specific mortality was 1% (two out of 199 patients). The 30-day re-admission rate was 9% (18 out
of 199 patients). Data for mortality risk stratification using the PESI tool were available for 187 patients
(94%), which included all patients who died by 30 days. The mean, minimum and maximum PESI scores
were 82.8, 19 and 199, respectively. When patients were stratified by PESI score, 30-day all-cause mortality
was 0.94% (one out of 106) in low risk patients and 3.7% (three out of 81) in intermediate-to-high risk
patients. The corresponding PE-specific mortality rates were 0% and 2.5% (two out of 81 patients).
Clinical characteristics and severity status of ambulated versus admitted PE patients
Admitted patients had significantly higher pulse rate, greater use of oxygen, lower oxygen saturation and
lower temperature than ambulated patients (table 1). The PESI score was significantly higher in admitted
patients; however, there was no difference in the proportion of patients (ambulated or admitted) who had
an intermediate-to-high risk PESI score. Using the current BTS guideline criteria for admission (based on
PESI score) there would have been 52 more admissions to hospital, a doubling of the admission rate [12].
There was no significant difference in re-admission rate or mortality in admitted patients; however, the
troponin level was significantly higher in admitted patients. We examined whether a greater proportion of
patients arriving on the AAU in the morning (before 13:00) were ambulated compared to those who
arrived after 13:00. We found that a significantly higher proportion of the patients seen in the morning
were ambulated.
Radiological findings in ambulated versus admitted patients
There were no significant differences in radiological findings between admitted and ambulated patients
(table 2). There was also no difference in the proportion of patients who had been diagnosed with PE
incidentally, having had a CT scan for an alternative reason such as cancer staging follow-up.
TABLE 1 Characteristics of ambulated and admitted patients
Variable Ambulated (n=136) Admitted (n=51) p-value
Age years (mean) 61.3 65.8 0.14
Male gender 65 (47.8) 23 (45.1) 0.87
Pulse rate beats·min−1 82.4 93.1 0.0001
Systolic BP mmHg 137.3 136.2 0.73
Oxygen saturation % 95.9 93.6 0.000005
Use of oxygen 2 (1.5) 19 (37.3) 0.0001
Respiratory rate breaths·min−1 17.8 20.0 0.0001
Temperature °C 36.4 36.6 0.03
Altered mental status 0 (0) 1 (1.8) 0.27
Heart failure 6 (4.4) 7 (13.7) 0.057
Cancer 27 (19.9) 9 (17.6) 0.89
Lung disease 26 (19.1) 13 (25.5) 0.45
PESI score 79.6 92.0 0.014
Intermediate-to-high risk patients 52 (38.2) 29 (56.9) 0.66
Troponin ng·mL−1 0.003 (n=79) 0.087 (n=34) 0.7×10−6
Morning arrival 91 (66.9) 19 (37.3) 0.0005
Re-admission rate 13 (9.6) 2 (3.9) 0.36
All-cause mortality 1 (0.7) 3 (5.9) 0.0625
Data is presented as n or n (%) unless otherwise stated. BP: blood pressure. PESI: Pulmonary Embolism
Severity Index.
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Further analysis of the subset of PESI score determined intermediate-to-high risk patients
We ambulated 52 patients with PESI scores in the intermediate-to-high risk category. A further 29 patients
with intermediate-to-high risk PE were admitted. The mean PESI scores in the ambulated and admitted
patients were 110.8 and 114.1, respectively, both being in the category of high risk (PESI score 106–125)
(table 3). Admitted patients had significantly higher pulse rates and respiratory rates, with lower oxygen
saturations, and were more likely to be using supplemental oxygen. This suggests physicians place a higher
value on physiological parameters of risk than cancer in deciding on when to admit patients.
Mortality in ambulated and admitted patients
To further assess the factors associated with mortality at 30 days in our cohort, we checked the causes of
death and the timing of mortality in relation to assessment on the AAU (table 4). Only one of the four
patients who died had been ambulated and the other three patients were admitted. The ambulated patient
had metastatic cancer and died of sepsis 16 days after assessment on the AAU. Of the three patients who
were admitted from the AAU, two died from PE the day following admission and one died from
pulmonary fibrosis 21 days later. These data suggest death from PE is uncommon and, notably, both
deaths from PE occurred within 48 h of presentation at the AAU.
Finally, we compared the clinical and radiological features of the patients who had died within 30 days to
those of survivors, irrespective of ambulation status (table 5). Overall, there were no statistically significant
differences although the small number of deaths limited the power of this analysis. However, there were
trends towards deceased patients being older, having a higher PESI score, greater oxygen use and
pre-existing lung disease.
Discussion
The development of ambulatory medicine units in the UK has expanded, with a recent survey of 132 acute
care hospitals finding that over 90% have an ambulatory emergency care service [14]. Whereas lower limb
deep vein thrombosis (DVT) is almost always managed as an outpatient, traditional practice has been to
admit patients with PE, mainly due to the risk of deterioration and death [15]. The typical duration of
admission for PE is about 3 to 6 days [16, 17]. The introduction of directly acting oral anticoagulants has
facilitated the outpatient management of PE by removing the need for cumbersome inpatient titration of
warfarin [18]. The safe utilisation of ambulatory care services for patients with suspected PE could,
amongst other benefits, reduce hospital bed usage. Guidelines from the BTS published in 2018
recommend ambulation for patients with low predicted mortality risk as defined by a validated clinical
scoring tool, but admission for patients with intermediate-to-high predicted mortality risk [12]. We
examined the outcomes of nearly 200 patients with PE who were assessed on our AAU, with particular
attention to the outcomes of intermediate-to-high risk patients who were ambulated.
We ambulated about 75% of PE patients, in keeping with the expected 60–90% range documented in the
Directory of Ambulatory Emergency Care produced by the National Health Service (NHS) Ambulatory
Emergency Care Network [19]. From our cohort of ambulated patients more than a third were classed as
intermediate-to-high risk based on the PESI scoring system (the most validated and widely-used risk
stratification tool) [4].
The approach advised in the recent BTS guideline is that patients with an intermediate-to-high risk PESI
score are admitted to hospital [12]. The basis for admitting these patients is that a higher PESI score
indicates a greater mortality risk and there is an assumption that admission might in some way mitigate
this risk. This accords with the ESC guidelines that recommend admission for patients with
intermediate-to-high risk PE. However, this recommendation is based on a single randomised study of
TABLE 2 Radiological findings in ambulated and admitted patients
Radiological finding Ambulated Admitted p-value
Bilateral# 91/134 (67.9) 38/49 (77.6) 0.28
RV strain¶ 24/129 (18.6) 15/50 (30) 0.15
Saddle embolus¶ 3/129 (2.3) 1/50 (2) 1.0
Sub-segmental¶ 12/128 (9.4) 3/50 (6) 0.67
Incidental finding¶ 8/136 (5.9) 2/50 (4) 1.0
Data is presented as n/n (%). RV: right-ventricular. #: finding based on computed tomography pulmonary
angiography (CTPA) or nuclear perfusion scanning; ¶: finding based on CTPA.
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non-shocked PE patients, with either right-ventricular (RV) dysfunction or a positive troponin test, in
which thrombolysis did not improve mortality compared to standard care [11, 13]. The evidence-based
rationale for admission is therefore unclear and, in the absence of compelling evidence for specific
admission criteria, the BTS guideline threshold for admission would appear to be based on an arbitrary
mortality threshold-this parallels the use of the popular CURB-65 mortality risk score, which is used as a
criterion for admission in community-acquired pneumonia (CAP) [20]. Patients with a CURB-65 score of
0–1, which confers a mortality rate of less than 3%, are considered potentially suitable for ambulation [21].
In our study, one of the 52 patients ambulated with intermediate-to-high risk died within 30 days. This
mortality rate is in line with that of the low risk cohort from the study in which the PESI tool was derived [4].
Furthermore, in our study, the cause of death was unrelated to PE and this may indicate that within the
intermediate-to-high risk group physicians are able to identify patients who are at a low risk of death. We
found that within the intermediate-to-high risk cohort the ambulated patients had significantly better
heart rates, respiratory rates and oxygen saturations, and less need for oxygen, despite having a similar
PESI score. This suggests that clinicians place emphasis on basic vital signs in making decisions on
ambulation.
Other factors that could be used to further stratify risk in patients with intermediate-to-high risk PESI
scores include radiological markers of cardiac compromise or biochemical measurements of troponin and
BNP. The presence of right-heart strain on CTPA had no effect on the decision to ambulate and did not
influence mortality. This is consistent with the finding that, in normotensive PE patients (representing
95% of PE patients, PESI score not reported), RV dilatation (a measure of RV dysfunction) was not
associated with increased mortality [22]. In another study, which did not stratify patients using a risk
TABLE 3 Comparison of patients with a non-low risk Pulmonary Embolism Severity Index
(PESI) score who were ambulated or admitted
Variable Ambulated (n=52) Admitted (n=29) p-value
Age years (mean) 74.6 76.2 0.53
Male gender 28 (53.8) 11 (38) 0.63
Pulse rate beats·min−1 84.3 95 0.003
Systolic BP mmHg 136.9 137.4 0.91
Oxygen saturation % 95.3 92.4 0.001
Use of oxygen 2 (3.8) 12 (41.3) 0.0007
Respiratory rate breaths·min−1 18 20.9 0.004
Temperature °C 36.2 36.5 0.069
Altered mental status 0 (0) 1 (3.4) 0.36
Heart failure 5 (9.6) 7 (24.1) 0.15
Cancer 26 (50) 9 (31) 0.11
Lung disease 20 (38.4) 11 (38) 0.85
PESI score 110.8 114.1 0.51
Troponin ng·mL−1 (n=22) 0.01 0.07 0.06
Data is presented as n or n (%), unless otherwise stated. BP: blood pressure.
TABLE 4 Detailed analysis of patients who died within 30 days of ambulatory assessment unit
attendance
Patient Admission
status
Age
years
(mean)
PESI
score
Comorbidity Cause of
death
Time to
death
days
Scan
1 Admitted 70 70 Nil PE 1 No scan
2 Admitted 80 103 Lung Pulmonary
fibrosis
21 Bilateral
sub-segmental
3 Admitted 83 130 Lung PE 1 Bilateral
4 Ambulated 58 118 Metastatic
cancer
Sepsis 16 Unilateral
PESI: Pulmonary Embolism Severity Index; PE: pulmonary embolism.
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calculator, there was no effect of clot burden on short-term mortality; however, RV dysfunction was
associated with mortality [23].
In many cases a troponin test may be sent as part of the initial diagnostic work-up of chest pain to help
exclude a myocardial infarction. Troponin level was measured in most patients in our cohort and we
found that, using a standard troponin assay (not high sensitivity), the mean troponin level was only
slightly above the threshold for positivity (in keeping with the BTS guideline recommendation that a
substantially raised troponin should prompt consideration of an alternative diagnosis other than PE) [12].
A meta-analysis of nine studies showed that the standard troponin assay is not a useful discriminator of
mortality risk in normotensive PE patients [24]. Nevertheless, the troponin level was significantly lower in
our ambulated patients, which is consistent with clinicians regarding troponin as a useful biomarker in
ambulatory decision making.
The use of BNP was infrequent in our cohort of patients, likely in part because the turnaround time was
several days for a laboratory measurement and near patient testing was only latterly introduced. A
meta-analysis of nine studies investigating the association of BNP and mortality in PE patients without
cardiogenic shock found that a normal BNP level had a 99% negative predictive value (NPV) for short
term death [25]. Future studies evaluating the use of BNP levels in making ambulation decisions for
patients with intermediate-to-high risk PESI scores may be valuable.
In addition to clinical features, we also found that the time of day when the patient was assessed affected
the admission rate. Patients were more likely to have been ambulated if they arrived before 13:00. This
may reflect a greater period of time to observe patients arriving early in the day and so greater clinician
confidence that the patient trajectory was trending to improvement. A range of other factors may affect the
ambulation rate during the day. Staff may be fresher and more able to make challenging decisions in the
morning and morning assessment may give time for other social aspects of care to be arranged. Some
patients may have been seen and given an immediate treatment dose of anticoagulant the previous day in
the emergency department or at the out of hours GP practise, and then brought back for an assessment on
the ambulatory unit the next morning. In effect these patients would have already demonstrated a period
of stability that would have been reassuring. Further studies are needed to assess if this is a general trend
across other diseases seen on ambulatory care units.
For patients who have been admitted from the ambulatory unit, another clinical challenge is deciding
when patients can be safely discharged once they no longer require treatment that requires hospital
admission (such as supplemental oxygen). In this regard, a notable finding in our study was that deaths
from PE occurred within 1–2 days of admission. We studied mortality at 30 days as it is highly unlikely
that a potentially ambulatory patient would be admitted for PE for longer than 30 days under most
circumstances. As such this timeframe covers the period of key relevance to the acute management
problem facing clinicians when selecting patients for ambulation. The PESI score is a prediction tool for
30-day mortality and most PE studies report only 30-day mortality and do not provide more granular data
TABLE 5 Comparison of severity factors in surviving patients and patients deceased within
30 days of ambulatory assessment unit attendance with pulmonary embolism (PE)
Variable Surviving (n=183) Deceased (n=4) p-value
Age years (mean) 62.3 72.75 0.25
PESI score 82.3 105.2 0.15
Cancer 35 (19.1) 1 (25) 0.58
Heart failure 13 (7.1) 0 (0) 1.0
Lung disease 37 (20) 2 (50) 0.19
Ambulated 135 (74) 1 (25) 0.063
Troponin ng·mL−1 0.027 (n=110) 0.07 (n=3) 0.40
D-dimer ng·mL−1 6120 9261 0.54
Oxygen use 19 (10.4) 2 (50) 0.063
Saddle embolus 4/176 (2.3) 0/3 (0) 1.0
Right-heart strain 39/175 (22.3) 0/3 (0) 1.0
Bilateral PE 127/180 (70.1) 2/3 (66.7) 1.0
Sub-segmental 14/175 (8) 1/3 (33.3) 0.23
Incidental finding 10/183 (5.5) 0/4 (0) 1.0
Data is presented as n, n (%) or n/n (%), unless otherwise stated. PESI: Pulmonary Embolism Severity
Index.
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on time to mortality. In a study assessing daily mortality out to 5 days in 298 patients hospitalised with PE
there was one death and this occurred on day four [16]. It would be helpful if daily PE death rates are
reported in future studies.
Beyond the risk of mortality, a further concern about ambulating more patients with PE is whether this
adversely affects the re-admission rate. Reassuringly, our analysis found that this was not the case for
re-admissions up to 30 days following diagnosis. This is consistent with a randomised controlled trial of
ambulatory management for low risk PE, which found no difference in unplanned healthcare utilisation
by 90 days [7].
Limitations
Our study has a number of limitations that could be usefully addressed in the future. We analysed the first
observations recorded when the patient arrived on the AAU and were therefore not able to assess rapid
trends in improvement or deterioration that would have affected the decision to ambulate. On our unit,
ambulatory care visits can span several hours and this could have provided the opportunity to observe
trends in clinical parameters that facilitated the selection of suitable patients for ambulation. Although
little is known about the impact of changes in the PESI score within a several hour period, by 48 h the
PESI score is reduced to the low-risk category in 27.3% of patients who are intermediate-to-high risk at
diagnosis [26]. Patients with a falling PESI score have a substantially lower mortality than those whose
score remains elevated [26]. In some patients, PE can be associated with severe pleuritic chest pain that
requires strong opioid analgesia. This is a criterion for which admission is recommended [12]; however,
we did not assess pain or analgesia usage in our study. The retrospective design of our study means that it
is not possible to ascertain all the factors that were used in the referral for consideration of ambulatory
care, or in the decision to ambulate a patient. Several other factors that we did not assess may affect
ambulation status including social support status and concurrent active illnesses. We applied the PESI
score retrospectively and therefore we cannot determine precisely how the score was or was not used at the
time of the patient being assessed. Prospective studies would be useful to analyse the basis of this decision
making in real time. Echocardiography was not routinely used in the initial work-up of patients with PE.
It is possible that some patients had echocardiography, but this data was not collected. In general, patients
were referred to our ambulatory unit because the referring clinician and/or the receiving ambulatory
physician believed that there was a reasonable prospect of ambulation and we did not have formal referral
criteria. For this reason, our results may not be generalisable to all cases of PE, for example, those in
critically ill patients.
We have received positive feedback from patients about their ambulatory care, but we have not
systematically studied the impact of our approach on patient satisfaction. The number of times a patient is
asked to return to the hospital for follow-up appointments might affect satisfaction, but we did not assess
this in this study. Published reports indicate that patient satisfaction is generally high among PE patients
treated as outpatients [7, 27, 28].
Conclusions
We operated an inclusive approach to acceptance of referrals to the AAU for suspected PE and this led to
over a third of patients presenting with clinical features for which hospital admission is recommended
under current guidelines. However, 64% of these patients were ambulated rather than admitted and the
mortality rate remained low. The data demonstrate that selected patients with intermediate-to-high risk
PESI scores can be safely ambulated if the patient is involved in shared decision-making regarding the
level of acceptable risk. Our study supports the development of future prospective studies designed to aid
clinicians in selecting patients who have intermediate-to-high risk PESI scores, but who may still be safely
ambulated, thereby increasing the opportunity for outpatient treatment of PE.
Conflict of interest: None declared.
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